ASH 2022 | ITHACA trial results: combination of isatuximab, lenalidomide & dexamethasone for high-risk SMM
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the findings of the randomized Phase III ITHACA Study which compared the efficacy of the addition of isatuximab, a CD38-directed antibody, to lenalidomide and dexamethasone (len-dex) with len-dex alone for the treatment of patients with high-risk smoldering multiple myeloma (SMM) (NCT04270409). So far, results have indicated that the novel regime is well tolerated by patients with SMM. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sognef: Honoraria; Bristol Myers Squibb: Honoraria; GSK: Honoraria; Huron Consulting: Honoraria; Veeva Systems: Honoraria; Vor Biopharma: Honoraria; Aptitude Health: Honoraria; Sanofi: Honoraria; Menarini Silicon Biosystems: Honoraria; Window Therapeutics: Other: Advisory board participation; The Binding Site: Honoraria; Takeda: Honoraria; Pfizer: Honoraria; Oncopeptides: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Adaptive: Honoraria; AbbVie: Honoraria; Novartis: Research Funding; Celgene: Research Funding.
